Recent Finacing
Recent Raise
Alpha Fusion develops Astatine‑211 targeted‑alpha radiopharmaceuticals, advancing multiple clinical programs (Phase I thyroid, prostate), building cyclotron‑based At‑211 supply, GMP manufacturing, and CMC/research capabilities.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors